HCV(CMIA)

ʻAʻole maopopo ka pathogenesis o ka hepatitis C.Ke hana hou ka HCV i loko o nā puʻupaʻa o ke ake, hoʻololi ia i ke ʻano a me ka hana o nā pūnaʻi ate a i ʻole ke keʻakeʻa i ka synthesis o nā protein cell ate, hiki ke hoʻohaʻahaʻa a me ka necrosis o nā pūnaʻi ate, e hōʻike ana i ka HCV e hōʻino pololei i ke ake a ke pāʻani nei i ka pathogenesis.Eia nō naʻe, manaʻo ka poʻe makemakika he mea koʻikoʻi ka hopena immunopathological cellular.Ua ʻike lākou ʻo ka maʻi hepa C, e like me ka maʻi hepa B, loaʻa ka CD3+ infiltrating cell i loko o kāna mau kiko.Hoʻopiʻi pono nā pūnaewele T Cytotoxic (TC) i nā keena i hoʻopaʻa ʻia o ka maʻi HCV, hiki ke hōʻino i nā pūnaʻi ate.

RIA a ELISA paha

Ua hoʻohana ʻia ʻo Radioimmunodiagnosis (RIA) a i ʻole enzyme-linked immunosorbent assay (ELISA) e ʻike i ka anti HCV i loko o ka serum.I ka makahiki 1989, Kuo et al.ua hoʻokumu i kahi ala radioimmunoassay (RIA) no ka anti-C-100.Ma hope mai, ua hoʻomohala ʻo Ortho Company i kahi enzyme-linked immunosorbent assay (ELISA) e ʻike ai i ka anti-C-100.Hoʻohana ʻia nā ʻano ʻelua i ka hū recombinant i hōʻike ʻia i ka virus antigen (C-100-3, he protein i hoʻopaʻa ʻia e NS4, he 363 amino acids), ma hope o ka hoʻomaʻemaʻe ʻana, ua uhi ʻia me kahi wahi liʻiliʻi o nā lua pā palaka, a laila hoʻohui ʻia me ka serum i hoʻāʻo ʻia.Hoʻohui ʻia ka antigen virus me anti-C-100 i ka serum i hoʻāʻo ʻia.ʻO ka hope, ua hoʻohui ʻia ka isotope a i ʻole ka enzyme labeled mouse anti human lgG monoclonal antibody, a hoʻohui ʻia ka substrate no ka hoʻoholo ʻana i ke kala.